Kinase targeting in Luminal B breast cancer: DTYMK.
Fuente:
Zenodo
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Recurso digital |
| Veröffentlicht: |
Zenodo
2025
|
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1866902022837501952 |
|---|---|
| author | Mamoor, Shahan |
| author_facet | Mamoor, Shahan |
| contents | <p dir="ltr">Breast cancer can be positive for expression of a hormone receptor (ESR/PGR/AR) or a growth factor receptor (ERBB2). Disease recurrence following disease remission (relapse), resistance to endocrine therapy or otherwise inadequate long-term control of disease are challenges that limit effectiveness of existing drugs that treat luminal A and luminal B subtype disease. Here we utilized whole transcriptome technologies (5, 6) to measure total transcription in the primary tumors of humans with luminal A and luminal B breast cancer. We describe one member of a group of kinases up-regulated and differentially expressed in human luminal B breast cancer, DTYMK, as a catalytically available enzyme and candidate therapeutic target for the adjunctive medical treatment of luminal B breast cancer. </p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_16921412 |
| institution | Zenodo |
| language | |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Kinase targeting in Luminal B breast cancer: DTYMK. Mamoor, Shahan <p dir="ltr">Breast cancer can be positive for expression of a hormone receptor (ESR/PGR/AR) or a growth factor receptor (ERBB2). Disease recurrence following disease remission (relapse), resistance to endocrine therapy or otherwise inadequate long-term control of disease are challenges that limit effectiveness of existing drugs that treat luminal A and luminal B subtype disease. Here we utilized whole transcriptome technologies (5, 6) to measure total transcription in the primary tumors of humans with luminal A and luminal B breast cancer. We describe one member of a group of kinases up-regulated and differentially expressed in human luminal B breast cancer, DTYMK, as a catalytically available enzyme and candidate therapeutic target for the adjunctive medical treatment of luminal B breast cancer. </p> |
| title | Kinase targeting in Luminal B breast cancer: DTYMK. |
| url | https://doi.org/10.5281/zenodo.16921412 |